Cart
sales@molnova.com
Abemaciclib metabolite M20
CAS No. 2138499-06-4
Abemaciclib metabolite M20 ( CDK4/6-IN-4; LSN3106726 )
Catalog No. M26100 CAS No. 2138499-06-4
Abemaciclib metabolite M20 is an active metabolite of Abemaciclib.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 258 | Get Quote |
|
| 10MG | 410 | Get Quote |
|
| 25MG | 678 | Get Quote |
|
| 50MG | 954 | Get Quote |
|
| 100MG | 1287 | Get Quote |
|
| 500MG | 2574 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameAbemaciclib metabolite M20
-
NoteResearch use only, not for human use.
-
Brief DescriptionAbemaciclib metabolite M20 is an active metabolite of Abemaciclib.
-
DescriptionAbemaciclib metabolite M20 is an active metabolite of Abemaciclib. Abemaciclib metabolite M20 is a selective CDK4/6 inhibitor and can be used for researches on the treatment of cancer.
-
SynonymsCDK4/6-IN-4; LSN3106726
-
PathwayAngiogenesis
-
TargetCDK
-
RecptorPEGs
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2138499-06-4
-
Formula Weight522.6
-
Molecular FormulaC27H32F2N8O
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(CO)n(C(C)C)c4c3)nc2)CC1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562.
molnova catalog
related products
-
CDK4/6-IN-6
CDK4/6-IN-6 is a potent CDK4/CDK6 inhibitor with Ki of 0.6 nM and 13.9 nM for CDK4/Cyclin D1 and CDK6/Cyclin D3, respectively.
-
CDK9-IN-2
CDK9-IN-2 is a potent and selective CDK9 inhibitor with IC50 of <8 nM, example 4 in patent WO2011026917A1.
-
THZ2
THZ2, an analogue of THZ1 with improved pharmacokinetic features, is a potent, selective CDK7 inhibitor with IC50 of 13.9 nM, displays a 5-fold improved half-life in vivo compared with THZ1.
